HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.